Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Total Current Liabilities: 2010-2025

Historic Total Current Liabilities for Ironwood Pharmaceuticals (IRWD) over the last 15 years, with Sep 2025 value amounting to $242.5 million.

  • Ironwood Pharmaceuticals' Total Current Liabilities rose 391.07% to $242.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $242.5 million, marking a year-over-year increase of 391.07%. This contributed to the annual value of $38.8 million for FY2024, which is 85.93% down from last year.
  • As of Q3 2025, Ironwood Pharmaceuticals' Total Current Liabilities stood at $242.5 million, which was up 4.29% from $232.5 million recorded in Q2 2025.
  • Ironwood Pharmaceuticals' 5-year Total Current Liabilities high stood at $305.4 million for Q2 2023, and its period low was $23.3 million during Q2 2022.
  • In the last 3 years, Ironwood Pharmaceuticals' Total Current Liabilities had a median value of $232.5 million in 2025 and averaged $163.2 million.
  • In the last 5 years, Ironwood Pharmaceuticals' Total Current Liabilities spiked by 1,210.80% in 2023 and then slumped by 85.93% in 2024.
  • Quarterly analysis of 5 years shows Ironwood Pharmaceuticals' Total Current Liabilities stood at $161.7 million in 2021, then crashed by 84.21% to $25.5 million in 2022, then skyrocketed by 981.69% to $276.1 million in 2023, then tumbled by 85.93% to $38.8 million in 2024, then soared by 391.07% to $242.5 million in 2025.
  • Its last three reported values are $242.5 million in Q3 2025, $232.5 million for Q2 2025, and $48.1 million during Q1 2025.